UK markets closed

Cyclo Therapeutics, Inc. (CYTH)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.4600-0.0100 (-0.68%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 42.21M
Enterprise value 34.00M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)22.30
Price/book (mrq)8.87
Enterprise value/revenue 31.59
Enterprise value/EBITDA -1.70

Trading information

Stock price history

Beta (5Y monthly) -0.15
52-week change 36.52%
S&P500 52-week change 324.19%
52-week high 32.5700
52-week low 30.8900
50-day moving average 31.4794
200-day moving average 31.4650

Share statistics

Avg vol (3-month) 394.4k
Avg vol (10-day) 343.59k
Shares outstanding 528.72M
Implied shares outstanding 628.72M
Float 815.87M
% held by insiders 139.48%
% held by institutions 19.77%
Shares short (15 Apr 2024) 475.29k
Short ratio (15 Apr 2024) 40.64
Short % of float (15 Apr 2024) 40.30%
Short % of shares outstanding (15 Apr 2024) 40.26%
Shares short (prior month 15 Mar 2024) 4112.59k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 309 Dec 2020
Ex-dividend date 4N/A
Last split factor 21:100
Last split date 309 Dec 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,811.99%

Management effectiveness

Return on assets (ttm)-143.52%
Return on equity (ttm)-730.48%

Income statement

Revenue (ttm)1.08M
Revenue per share (ttm)0.07
Quarterly revenue growth (yoy)66.70%
Gross profit (ttm)N/A
EBITDA -20.03M
Net income avi to common (ttm)-20.06M
Diluted EPS (ttm)-1.2300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)9.25M
Total cash per share (mrq)0.32
Total debt (mrq)1.03M
Total debt/equity (mrq)21.72%
Current ratio (mrq)1.46
Book value per share (mrq)0.17

Cash flow statement

Operating cash flow (ttm)-16.19M
Levered free cash flow (ttm)-8.26M